Top Markets
Coin of the day
Sigilon Therapeutics, Inc. Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc.

SGTX
शेयरों में रैंक #25416
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015,... Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.
शेयर मूल्य
$22.47
अंतिम समन्वयन: 2023-08-18
मार्केट कैप
$49.76M
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Sigilon Therapeutics, Inc. (SGTX)

श्रेणी

Sigilon Therapeutics, Inc. (SGTX) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $22.30 (2023-08-01 को)

दिन का सबसे निम्न समापन मूल्य: $453.71 (2020-12-01 को)
Sigilon Therapeutics, Inc. के स्टॉक मूल्य का इतिहास 2020 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
वर्ष प्रदर्शन
2023 400.06%
2022 -87.99%
2021 -91.82%
2020 0.00%
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
कंपनी स्टॉक मूल्य परिवर्तन 1व% देश
$539.14 35.65%
US
$1.04K 56.21%
NL
$117.80 -18.86%
AU
$761.87 8.65%
CH
$130.43 397.46%
US